Bupropion, sold under brand names including Wellbutrin and Zyban, is one of the most commonly prescribed antidepressants and smoking cessation aids in the United States. It is also one of the most frequently documented causes of a false positive amphetamine result on a urine drug screen. If an employee, patient, or candidate takes bupropion and then screens non-negative for amphetamines on an initial immunoassay, that result does not mean the person used methamphetamine, Adderall, or any other amphetamine. It means the screening chemistry reacted to a compound that resembles amphetamine closely enough to trip the same antibody. Confirmation testing exists precisely to sort that out before anyone acts on the result.
Why bupropion looks like amphetamine to a screening test
Bupropion is chemically classified as an aminoketone, and its core structure includes a phenyl ring attached to an amine group, the same basic skeleton that defines amphetamine-type stimulants. The parent drug is broken down in the liver into several metabolites, the most abundant of which is hydroxybupropion. According to the NIH Bookshelf clinical reference on bupropion, the drug undergoes extensive hepatic metabolism, and hydroxybupropion circulates at levels many times higher than the parent compound. That metabolite retains enough structural similarity to amphetamine that antibody-based immunoassay screens, which detect a class of molecules rather than one specific drug, can bind to it and flag a presumptive positive.
This is not a rare or obscure interaction. A published analysis of amphetamine-positive urine specimens screened with the Syva EMIT II immunoassay found that a majority of the amphetamine screens that failed gas chromatography confirmation could be traced to patients taking bupropion, making it the single most common driver of false positive amphetamine results in that population. The full study is available through the National Library of Medicine and lays out both the frequency of the problem and the immunoassay platforms involved.
Which assays are affected
Cross-reactivity depends on the specific immunoassay chemistry, its antibody design, and its cutoff concentration, not on the drug class alone. Bupropion and its metabolites have been documented to interfere with EMIT II amphetamine immunoassays and with CEDIA amphetamine and LSD assays. Point of care cup tests and lab-based immunoassay screens both rely on similar antibody chemistry, so the same interference can appear at the collection site or in the lab's first-pass screen. It does not mean every bupropion prescription produces a positive screen. Interference is concentration-dependent, and dose, metabolism speed, hydration, and the specific cutoff the assay uses all affect whether a given specimen crosses the threshold.
How GC-MS and LC-MS confirmation clears it
Immunoassay screens are built for speed and sensitivity, not specificity. They are designed to catch anything that resembles the target class so that nothing slips through, and that design tradeoff is exactly why cross-reactivity happens. Confirmation testing works differently. Gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry separate and identify molecules by their exact mass and structure, so they distinguish true amphetamine or methamphetamine from a structurally similar compound like hydroxybupropion. A specimen that screens non-negative for amphetamines but was actually reacting to bupropion will not confirm as amphetamine or methamphetamine on GC-MS or LC-MS, because those molecules are not present. Federal workplace testing rules under 49 CFR Part 40 require exactly this two-step process: an initial screen followed by confirmatory chromatography-mass spectrometry testing on any specimen that screens non-negative, before a Medical Review Officer ever reviews the result.
What to tell the MRO
If a confirmed positive result comes back and the person has a bupropion prescription, the review conversation with the Medical Review Officer is straightforward but should be handled carefully. Have the prescription information ready, including the prescribing clinician and the pharmacy that filled it, since the MRO will typically want to verify the prescription is legitimate and current. Mention the medication by name during the verification interview rather than waiting to be asked, since bupropion is not always volunteered by patients who do not realize it is relevant to a drug screen. The SAMHSA Medical Review Officer Guidance Manual lays out the verification interview process MROs follow for federally regulated testing, including how a legitimate medical explanation is documented and how it affects the reported result. In practice, if the confirmatory GC-MS or LC-MS result does not show amphetamine or methamphetamine, the bupropion explanation is moot because there is nothing to explain. The confirmation test itself, not the prescription, is what clears the record.
How employers should handle a non-negative screen
The single most important rule for employers is not to treat an initial screen as a final result. A non-negative immunoassay is a presumptive finding, not a verified positive, and taking disciplinary or hiring action based on the screen alone, before confirmation and MRO review are complete, creates real legal exposure and can penalize someone for a completely legitimate prescription. The correct sequence is to send the specimen for confirmatory testing, let the laboratory report a confirmed result to the MRO, and let the MRO complete the verification interview before any employment decision is made. Employers should also make sure their written drug testing policy spells out this sequence clearly, so supervisors are not tempted to act on a rapid cup result in the field. For a closer look at what happens between a non-negative screen and a verified result, see this article on what lab confirmation does after a non-negative screen.
Other medications linked to amphetamine false positives
Bupropion is common, but it is far from the only medication that can cross-react on an amphetamine immunoassay. The table below lists other documented sources of amphetamine or methamphetamine screen interference, based on published case reports and pharmacology references.
| Medication | Common use | Why it cross-reacts |
|---|---|---|
| Bupropion (Wellbutrin, Zyban) | Depression, smoking cessation | Hydroxybupropion metabolite shares a phenyl-amine backbone with amphetamine |
| Atomoxetine (Strattera) | ADHD treatment | Structural similarity documented to interfere with amphetamine immunoassays |
| Mexiletine | Cardiac arrhythmia | Case reports document amphetamine-class immunoassay cross-reactivity |
| Phentermine | Weight management | A true amphetamine-class stimulant that is expected to screen positive, not a false positive, but often confused with one |
| Ranitidine and related H2 blockers | Acid reflux | Older assay formulations were shown to cross-react at certain concentrations |
| Selegiline | Parkinson's disease, depression (MAO-B inhibitor) | Metabolized in part to amphetamine and methamphetamine, which can produce a true positive that looks unexpected |
Two related articles cover the amphetamine panel in more depth: why Adderall triggers amphetamine positives and how MRO review works, and why phentermine causes amphetamine false positives.
Why instant tests are screens, not final results
Rapid cup and dip card tests, whether used at a collection site, a clinic, or a workplace, are immunoassay screens by design. They are fast, inexpensive, and effective at ruling out a clean specimen, but they are not built to distinguish bupropion's metabolite from actual amphetamine at the molecular level. That distinction only happens with chromatography-mass spectrometry confirmation at a certified lab. Any testing program, whether it uses instant cups or lab-based screening, should be built with that two-step logic from the start: a fast initial screen to flag specimens that need a closer look, and confirmatory testing before anyone treats a result as final. Employers building or restocking a testing program can review the full range of drug testing cups, dip cards, and oral fluid kits available for point of care screening, alongside a confirmation lab partner for any specimen that comes back non-negative.
Frequently asked questions
Does Wellbutrin always cause a positive amphetamine screen?
No. Cross-reactivity depends on the dose, how quickly the individual metabolizes bupropion, the concentration of hydroxybupropion in the urine at the time of collection, and the specific cutoff level used by the immunoassay. Many people taking bupropion never screen non-negative for amphetamines. When it does happen, it is a known and well-documented interference pattern, not a rare fluke.
Will bupropion show up as methamphetamine instead of amphetamine?
The documented interference pattern for bupropion is with amphetamine immunoassays specifically, since its metabolites share structural features with amphetamine rather than methamphetamine. Confirmation testing separates the two compounds precisely, so a bupropion-related screening result should not confirm as either true amphetamine or methamphetamine.
Should I stop taking Wellbutrin before a drug test?
No. Stopping a prescribed antidepressant or smoking cessation medication to avoid a screening result is not advisable and is not necessary. The testing process is designed to catch this exact scenario through confirmation testing and MRO review. Disclosing the prescription during the verification interview is the correct step, not discontinuing the medication.
What should a candidate or employee do if bupropion causes a non-negative screen?
Keep the prescription information accessible and be ready to provide it during the Medical Review Officer's verification call. There is no need to preemptively explain a positive screen before it happens. If a confirmed result does show amphetamine, the MRO interview is the appropriate place to raise any prescribed medication as a potential explanation.
Can an employer take action based on the initial screen alone?
Doing so is not advisable and, for federally regulated testing under 49 CFR Part 40, is not permitted. The initial immunoassay is presumptive. Confirmatory testing and Medical Review Officer review are required steps before a result is reported as verified positive, and employment decisions should wait until that process is complete.
Related reading
This article is general information, not legal or medical advice. Drug testing policies and interpretation of screening results should be reviewed with a licensed Medical Review Officer, employment counsel, or healthcare provider familiar with the specific program and jurisdiction involved.
